57 related articles for article (PubMed ID: 2151849)
1. Mitoxantrone: bluebeard for malignancies.
van der Graaf WT; de Vries EG
Anticancer Drugs; 1990 Dec; 1(2):109-25. PubMed ID: 2151849
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a novel anthracycline derivative.
Koeller J; Eble M
Clin Pharm; 1988 Aug; 7(8):574-81. PubMed ID: 3048848
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer.
Bowers C; Adkins D; Dunphy F; Harrison B; LeMaistre CF; Spitzer G
Bone Marrow Transplant; 1993 Nov; 12(5):525-30. PubMed ID: 8298564
[TBL] [Abstract][Full Text] [Related]
4. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells.
Repetto L; Vannozzi MO; Balleari E; Venturino A; Granetto C; Bason C; Simoni C; Prencipe E; Queirolo P; Esposito M; Ghio R; Rosso R
Anticancer Res; 1999; 19(1B):879-84. PubMed ID: 10216510
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Büyükünal E; Derman U; Serdengecti S; Berkarda B
Chemioterapia; 1987 Oct; 6(5):377-9. PubMed ID: 3322590
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Lemez P; Maresová J
Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
11. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and toxicity of intrapleural mitoxantrone: apropos of 18 cases of pleural metastases of breast cancer].
Feuilhade F; Brun B; Calitchi E; Otzmeguine Y; Haddad E; Le Bourgeois JP; Pierquin B
Bull Cancer; 1989; 76(4):361-5. PubMed ID: 2665879
[TBL] [Abstract][Full Text] [Related]
13. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells.
Kluza J; Marchetti P; Gallego MA; Lancel S; Fournier C; Loyens A; Beauvillain JC; Bailly C
Oncogene; 2004 Sep; 23(42):7018-30. PubMed ID: 15273722
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
16. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
17. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.
Alberts DS; Surwit EA; Peng YM; McCloskey T; Rivest R; Graham V; McDonald L; Roe D
Cancer Res; 1988 Oct; 48(20):5874-7. PubMed ID: 3167842
[TBL] [Abstract][Full Text] [Related]
19. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
20. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
